Dogwood Therapeutics: inaasahan ang topline data ng Phase 2b CINP ng Halneuron sa taglagas ng 2026

Kinumpirma ng 8-K na ang Halneuron Phase 2b trial sa chemotherapy-induced neuropathic pain ay nasa tamang takbo na may 164 pasyenteng naka-enroll at ang top-line results ay nakatakda sa fall 2026. Bukod dito, tinanggap ng FDA ang SP16 IND para sa Phase 1b CIPPN study na magsisimula ng enrollment sa mid-2026.

Mahahalagang fact

Na-file: May 14, 2026, 12:50 PM
Kaganapan: Topline na resulta
Direksyon: Neutral
Kumpanya: DWTXDogwood Therapeutics
Asset: Halneuron
Pinagmulan: SEC 8-K
Kumpiyansa: May source
mga pasyenteng naka-enroll: 164

Sipi mula sa source

EX-99.1 2 dwtx-20260514xex99d1.htm EX-99.1 Exhibit 99.1 Dogwood Therapeutics Announces First Quarter 2026 Financial Results - Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy Induced Pain and Neuropathy – - Announces Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets with potential value up to $100M to Dogwood and its current and former shareholders - ALPHARETTA, Ga., May 14, 2026 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced financial results for the

SEC 8-K